Exact Sciences Acquires Rights to TARDIS Liquid Biopsy Technology

Exact Sciences, Inc., a Madison, Wisconsin–based provider of cancer screening and diagnostic tests, has acquired a worldwide exclusive license to the Targeted Digital Screening (TARDIS) “liquid biopsy” technology developed by the Translational Genomics Research Institute, an affiliate of City of Hope Comprehensive Cancer Center.

TARDIS offers a personalized approach to MRD testing through the tumor-guided detection and quantification of circulating tumor DNA (ctDNA). In a study published in Science Translational Medicine in 2019, TARDIS achieved up to a 100-fold improvement beyond the current limit of ctDNA detection in assessing molecular response and residual disease in 32 patients with early-stage breast cancer who were undergoing neoadjuvant therapy.


Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology. 1/13/2021. https://www.tgen.org/news/2021/january/13/exact-sciences-licenses-tardis/

McDonald BR, Contente-Cuomo T, Sammut SJ, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 2019;11(504):eaax7392. doi:10.1126/scitranslmed.aax7392



Tags: MRD, MRD testing, liquid biopsy

Theme picker